• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Senseonics Holdings Inc. (Amendment)

    3/20/23 4:35:05 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials
    Get the next $SENS alert in real time by email
    SC 13D/A 1 brhc10050015_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    Senseonics Holdings, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    81727U105
    (CUSIP Number)

    Kaiju Yamaguchi
    2-38-5 Nishishimbashi, Minato-ku, Tokyo
    105-8433 Japan
    Telephone: +81-3-5408-7280
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    March 13, 2023

    (Date of Event Which Requires Filing of This Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.


    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 81727U105
    13D/A
    Page 1 of 6 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    PHC Holdings Corporation
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Japan
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    86,892,237
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    86,892,237
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    86,892,237
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    15.41%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No. 81727U105
    13D/A
    Page 2 of 6 pages

    Item 1.
    Security and Issuer.

    This Schedule 13D/A (the “Amendment”) relates to the shares of Common Stock, $0.001 par value per share (the “Common Stock”), of Senseonics Holdings, Inc., a Delaware corporation (the “Issuer”) whose principal executive offices are located at 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005.

    Item 2.
    Identity and Background.

    (a)
    This Amendment is being filed by PHC Holdings Corporation, a corporation organized under the laws of Japan (“PHC Holdings” or the “Reporting Person”).
    (b)
    The address of the business office of PHC Holdings is: 2-38-5 Nishishimbashi, Minato-ku, Tokyo, 105-8433 Japan
    (c)
    PHC Holdings is engaged in the business of research, design, development, manufacturing and distribution of medical devices.
    (d)-(e)
    During the last five years, neither the Reporting Person nor, to the best of knowledge of the Reporting Person, any of the Related Persons (as defined below), (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    PHC Holdings is organized under the laws of Japan.

    The name, business address, present principal occupation or employment and citizenship of the executive officers and members of the board of directors of the Reporting Person (collectively, the “Related Persons”) is set forth on Schedule I hereto and is herein incorporated by reference.

    Item 3.
    Source and Amount of Funds or Other Consideration.

    The responses to Item 3 of the prior Schedule 13D (the “Prior 13D”) is incorporated herein by reference and the description of the transactions described therein, and the agreements entered into between the Issuer and the Reporting Person, are incorporated herein by reference to the disclosures set forth in the Prior 13D. Item 3 of the Prior 13D is hereby amended and restated in its entirety as follows.

    Pursuant to a Securities Purchase Agreement, dated as of March 13, 2023 (the “SPA”), by and between the Reporting Person and the Issuer, the Reporting Person purchased from the Issuer a stock purchase warrant (the “Purchase Warrant”) exercisable for an aggregate of 15,425,750 shares of Common Stock for a purchase price of $15,000,000.

    Pursuant to an Exchange Agreement dated as of March 13, 2023, by and between the Reporting Person and the Issuer, the Purchaser agreed to exchange $35,000,000 in aggregate principal amount of its Senior Secured Convertible Notes due October 31, 2024 of the Issuer for a stock purchase warrant exercisable for an aggregate of 68,525,311 shares of Common Stock (the “Exchange Warrant” and, collectively with the Purchase Warrant, the “Warrants”).   The transaction contemplated by the Exchange Agreement is expected to close on April 1, 2023, subject to the satisfaction of customary closing conditions for a transaction of this type.


    CUSIP No. 81727U105
    13D/A
    Page 3 of 6 pages

    Item 4.
    Purpose of Transaction.

    The responses to Item 4 of the Prior 13D is incorporated herein by reference and is hereby supplemented by adding the following:

    In connection with the Investor Rights Agreement between the Issuer and the Reporting Person, dated as of August 9, 2020, the Reporting Person has the right to designate two members of the board of directors of the Issuer. In addition, without limitation, the Reporting Person may engage in discussions with management, the board of directors of the Issuer, stockholders of the Issuer or other securityholders of the Issuer and other relevant parties or take other actions concerning any extraordinary corporate transaction (including but not limited to a merger, reorganization or liquidation) or the business, operations, assets, strategy, future plans, prospects, corporate structure, board composition, management, capitalization, dividend policy, charter, bylaws, corporate documents, agreements, de-listing or de-registration of the Issuer.

    Except as set forth above, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Person may change its purpose or formulate different plans or proposals with respect thereto at any time.

    Item 5.
    Interest in Securities of the Issuer.

    The information set forth in Items 2 and 3 of this Amendment and the cover pages of this Amendment is hereby incorporated by reference into this Item 5.

    (a) - (b) The Reporting Person beneficially owns 86,892,237 shares of Common Stock which is comprised of 2,941,176 shares of Common Stock issued to the Reporting Person on August 14, 2020 and the shares underlying the Warrants discussed in Item 3 above.   The Reporting Person’s beneficial ownership represents approximately 15.41% of the outstanding shares of the Issuer’s Common Stock, based on 479,780,414 shares of Common Stock outstanding as of March 13, 2023, as reported in the SPA and as adjusted in accordance with Rule 13d-3 under the Exchange Act.


    CUSIP No. 81727U105
    13D/A
    Page 4 of 6 pages

    (c) Except as described in Item 4 and Item 6, during the past 60 days none of the Reporting Persons or Related Persons has effected any transactions in the Common Stock.

    (d) None.

    (e)
    Not applicable.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Resale Registration Rights Agreement

    On March 13, 2023, the Issuer and the Reporting Person entered into a resale registration rights agreement (the “Resale Registration Rights Agreement”), pursuant to which the Issuer granted certain demand registration rights, short-form registration rights and piggyback registration rights to such shareholder. Any Registrable Securities (as defined in the Resale Registration Rights Agreement) will cease to be Registrable Securities when: (i) the Securities and Exchange Commission has declared a registration statement covering such securities effective and such securities have been disposed of pursuant to such effective registration statement; (ii) such securities are sold under circumstances in which all of the applicable conditions of Rule 144 under the Securities Act of 1933, as amended, are met and the legend restricting further transfer has been removed from the certificate for such securities; or (iii) such securities are no longer outstanding.

    The foregoing description of the Resale Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is filed as an exhibit to this Amendment, and incorporated herein by reference.

    Exchange Agreement

    On March 13, 2023, the Issuer and the Reporting Person entered into an Exchange Agreement in which the Reporting Person agreed to exchange $35,000,000 in aggregate principal amount of secured promissory notes of the Company for a stock purchase warrant exercisable for an aggregate of 68,525,311 shares of Common Stock. The transaction contemplated by the Exchange Agreement is expected to close on April 1, 2023, subject to the satisfaction of customary closing conditions for a transaction of this type.

    Securities Purchase Agreement

    On March 13, 2023, the Issuer and the Reporting Person entered into the SPA in which the Reporting Person agreed to purchase from the Issuer a stock purchase warrant exercisable for an aggregate of 15,425,750 shares of Common Stock.  The transaction contemplated by the SPA closed on March 13, 2023.

    Warrants

    Upon the closing of  the SPA Agreement, the Reporting Person received the Purchase Warrant, which is exercisable into an aggregate of 15,425,750 shares of Common Stock at a price of $0.001 per share.  Upon the closing of the Exchange Agreement, the Reporting Person will receive the Exchange Warrant, which is exercisable into an aggregate of 68,525,311 shares of Common Stock at a price of $0.001 per share.  The Warrants have no expiration date.

    The foregoing descriptions of the Exchange Agreement, the Securities Purchase Agreement, the Purchase Warrant and the Exchange Warrant do not purport to be complete and are qualified in their entirety by reference to the filed copies of such documents, copies of  which are filed with this Amendment and incorporated by reference herein.


    CUSIP No. 81727U105
    13D/A
    Page 5 of 6 pages

    Item 7.
    Materials to be Filed as Exhibits

    Exhibit
    Number

    Description
    Exhibit A

    Registration Rights Agreement by and between the Senseonics Holdings, Inc. and PHC Holdings Corporation (incorporated by reference to the Exhibit 4.1 to the Issuer’s Current Report on Form 8-K filed on March 15, 2023).
     
     
    Exhibit B

    Exchange Agreement by and between the Senseonics Holdings, Inc. and PHC Holdings Corporation (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on March 15, 2023).
     
     
    Exhibit C

    Securities Purchase Agreement by and between the Senseonics Holdings, Inc. and PHC Holdings Corporation (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on March 15, 2023).
         
    Exhibit D

    Warrant dated March 13, 2023 (incorporated by reference to Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed on March 15, 2023).


    CUSIP No. 81727U105
    13D/A
    Page 6 of 6 pages

    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: March 20, 2023

     
    PHC HOLDINGS CORPORATION
     
    By:
    /s/ Kaiju Yamaguchi
     
     
    Name: Kaiju Yamaguchi
     
    Title: Chief Strategy Officer
     

    Schedule I

    Directors of PHC Holdings Corporation

    The following sets forth the name and principal occupation of each of the directors of PHC Holdings Corporation. Each of such persons is a citizen of Japan other than Ivan Tornos and David Sneider who are citizens of United States of America.

    Name
    Principal Occupation
    Shoji Miyazaki
    President, Chief Executive Officer of PHC Holdings Corporation
    Koichiro Sato
    Senior Executive Vice President, Chief Operating Officer of PHC Holdings Corporation
    Hirofumi Hirano
    Chief Executive Officer, KKR Japan Limited
    Eiji Yatagawa
    Partner, KKR Japan Limited
    Sen Sakaguchi
    General Manager, Wellness Business Division, Wellness Business Unit of Mitsui & Co., Ltd.
    Kyoko Deguchi
    Vice Director, Doya Rehabilitation & Orthopedic Clinic
    Ivan Tornos
    Chief Operating Officer, Zimmer Biomet Group
       
    David Sneider
    Attorney



    Get the next $SENS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics

    - Agreement with Senseonics to transfer commercial activities would integrate Eversense manufacturing and distribution to accelerate growth PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE:SENS). The companies are targeting to unite Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026, subject to a definitiv

    9/3/25 7:22:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Reports Second Quarter Financial Results

    Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.6 million in the second quarter of 2025, an increase of 37% versus the second quarter of 2024, driven by 79% new patient growth in the U.S. over prio

    8/6/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Prince Douglas S was granted 17,069 shares, increasing direct ownership by 2% to 1,087,607 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    7/3/25 4:15:40 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Steven Edelman was granted 27,048 shares, increasing direct ownership by 2% to 1,263,001 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    7/3/25 4:15:32 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Roeder Douglas A was granted 30,987 shares, increasing direct ownership by 2% to 1,658,826 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    7/3/25 4:15:35 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Roeder Douglas A bought $37,500 worth of shares (75,000 units at $0.50), increasing direct ownership by 5% to 1,463,087 units (SEC Form 4)

    4/A - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/20/24 5:37:53 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Roeder Douglas A bought $135,500 worth of shares (325,000 units at $0.42), increasing direct ownership by 30% to 1,413,087 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/16/24 4:21:25 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Chief Financial Officer Sullivan Frederick T. bought $47,475 worth of shares (124,933 units at $0.38), increasing direct ownership by 5% to 2,478,844 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/12/24 7:04:14 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $SENS
    SEC Filings

    View All

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    H.C. Wainwright resumed coverage on Senseonics with a new price target

    H.C. Wainwright resumed coverage of Senseonics with a rating of Buy and set a new price target of $1.10

    6/2/25 8:54:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form EFFECT filed by Senseonics Holdings Inc.

    EFFECT - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/19/25 12:15:16 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form 424B3 filed by Senseonics Holdings Inc.

    424B3 - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/18/25 4:36:27 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form DEF 14A filed by Senseonics Holdings Inc.

    DEF 14A - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/18/25 7:30:29 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025. Management will hold a conference call to review the Company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by na

    7/16/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Reports First Quarter Financial Results

    Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.3 million in the first quarter of 2025CMS upda

    5/8/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials